NMTRQ
9 METERS BIOPHARMA INC
stockOTC
9 meters biopharma, inc., a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. the company's pipeline includes drug candidates for short bowel syndrome (sbs) and celiac disease. it is developing nm-002, a long-acting injectable glp-1 agonist that is in a phase 2 clinical trial for sbs; and larazotide, a phase 3-stage therapeutic in development for celiac disease. the company also develops nm-003, a proprietary long-acting glp-2 agonist; and nm-004, a double-cleaved mesalamine with an immunomodulator for developing rare and/or orphan indications. 9 meters biopharma, inc. is based in raleigh, north carolina.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.00 | 2026-11-04 | +9900.00% | 0.000 |
| 1M | 0.00 | 2026-10-19 | +9900.00% | -2005.387 |
| 3M | 0.00 | 2026-08-17 | +9900.00% | 63.989 |
| 6M | 0.00 | 2026-05-14 | +9900.00% | -245.955 |
| 1Y | 0.00 | 2025-11-12 | +9900.00% | -304.235 |
| 2Y | 0.00 | 2024-11-13 | +9900.00% | — |
| 5Y | 0.05 | 2023-07-26 | -99.80% | -95.048 |
9 METERS BIOPHARMA INC (OTC:NMTRQ) stock price today is $0.00, and today's volume is 154. NMTRQ is up 9900.000% today. The 30 day average volume is 19,724. NMTRQ market cap is $1,446 with 14.46M shares outstanding.